CALL/AMGEN/500/0.1/17.01.25 | Real-time BOERSE MUENCHEN 11:57:07 20/05/2024 pm IST | ||
| 0.103 EUR | -4.63% |
|
| Current month | +163.41% | ||
| 1 month | +145.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 20/24/20 | 0.103 | -4.63% |
| 17/24/17 | 0.108 | -9.24% |
| 16/24/16 | 0.119 | +6.25% |
| 15/24/15 | 0.112 | +15.46% |
| 14/24/14 | 0.097 | +7.78% |
Real-time BOERSE MUENCHEN
Last update May 20, 2024 at 11:57 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Goldman Sachs |
| WKN | GG1SV2 |
| ISIN | DE000GG1SV27 |
| Date issued | 03/01/2024 |
| Strike | 500 $ |
| Maturity | 17/01/2025 (242 Days) |
| Parity | 10 : 1 |
| Emission price | 0.07 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.145 € |
|---|---|
| Lowest since issue | 0.029 € |
| Spread | 0.1 € |
| Spread % | 50.00% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
312.5
USD
Average target price
316.1
USD
Spread / Average Target
+1.15%
- Stock Market
- Warrants
- Warrant
